Significant positive results with jaguar health's crofelemer for chronic refractory diarrhea in ibs-d, presented at american college of gastroenterology annual meeting

It is estimated that 10-15% of people in the united states have ibs san francisco, ca / accesswire / october 29, 2024 / jaguar health, inc. (nasdaq:jagx) ("jaguar") family company napo pharmaceuticals ("napo") today announced that the abstracts are now available for two independent investigator-initiated studies of crofelemer, napo's novel, plant-based oral prescription drug, that show a benefit in patients with chronic refractory diarrhea and are the subject of poster presentations taking place today, october 29, 2024, at the american college of gastroenterology annual scientific meeting (acg 2024) in philadelphia, pennsylvania. descriptions of both studies appear below, along with a link to the virtual acg 2024 eposter hall page for each study - which display the poster for each study and provide a short audio presentation of the posters.
JAGX Ratings Summary
JAGX Quant Ranking